Clinical Trial Search

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 91; 31; 26 Participants

Primary: Number of Participants With Adverse Events — 2; 1; 5; 4 Participants

Primary: Forced Vital Capacity — 1.4; 1.4; 1.5 liters — p=0.3904

Primary: Fasting Glucose — 93; 102 mg/dL

Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension

Primary: Bayley III Gross Motor Scaled Score (Change From Baseline to 12 Month) — 4.8 units on a scale

Primary: Body Composition (Body Fat) — 172.1; 232.7; 180.2; 274.8 g/Kg of body weight — p=<0.05

Primary: Plasma Follistatin

Primary: Percentage of Participants Treated With Sevasemten Experiencing AEs — 100 percentage of participants

Primary: Change From Baseline in Muscle Tissue PGC1alpha (AU) at 8 Weeks — 0.55; 0.86 AU — p=0.0434

Primary: Pharmacokinetics Outcome: Absolute Values of (+)-Epicatechin Serum Concentration, Pre-dose (Trough) and 2 Hours Post-dose (Peak) — 15.1; 33.9; 20.6; 481.2 nM — p=0.0482

Primary: Number of Participants With Adverse Events Related to AVI-4568 — 0; 0 Participants

Primary: Left Ventricular Strain — 0.2; 0.4 Percent change in circumference — p=0.5867

Primary: Incidence of Treatment-Emergent Adverse Events — 14; 9; 10 Participants

Primary: The Relative Change in Peak Systolic Radial Strain of the Left Ventricle (LV) Inferolateral Wall From Baseline (at Screening) to Week 52, Assessed by Color Doppler…